2022-09-012023-08-312023-08-31false08649020LARGE ATTALE MEDICAL LTD2024-05-01iso4217:GBPxbrli:pure086490202022-09-01086490202023-08-31086490202022-09-012023-08-31086490202021-09-01086490202022-08-31086490202021-09-012022-08-3108649020bus:SmallEntities2022-09-012023-08-3108649020bus:AuditExempt-NoAccountantsReport2022-09-012023-08-3108649020bus:FullAccounts2022-09-012023-08-3108649020bus:PrivateLimitedCompanyLtd2022-09-012023-08-3108649020core:WithinOneYear2023-08-3108649020core:AfterOneYear2023-08-3108649020core:WithinOneYear2022-08-3108649020core:AfterOneYear2022-08-3108649020core:ShareCapital2023-08-3108649020core:SharePremium2023-08-3108649020core:RevaluationReserve2023-08-3108649020core:OtherReservesSubtotal2023-08-3108649020core:RetainedEarningsAccumulatedLosses2023-08-3108649020core:ShareCapital2022-08-3108649020core:SharePremium2022-08-3108649020core:RevaluationReserve2022-08-3108649020core:OtherReservesSubtotal2022-08-3108649020core:RetainedEarningsAccumulatedLosses2022-08-3108649020core:LandBuildings2023-08-3108649020core:PlantMachinery2023-08-3108649020core:Vehicles2023-08-3108649020core:FurnitureFittings2023-08-3108649020core:OfficeEquipment2023-08-3108649020core:NetGoodwill2023-08-3108649020core:IntangibleAssetsOtherThanGoodwill2023-08-3108649020core:ListedExchangeTraded2023-08-3108649020core:UnlistedNon-exchangeTraded2023-08-3108649020core:LandBuildings2022-08-3108649020core:PlantMachinery2022-08-3108649020core:Vehicles2022-08-3108649020core:FurnitureFittings2022-08-3108649020core:OfficeEquipment2022-08-3108649020core:NetGoodwill2022-08-3108649020core:IntangibleAssetsOtherThanGoodwill2022-08-3108649020core:ListedExchangeTraded2022-08-3108649020core:UnlistedNon-exchangeTraded2022-08-3108649020core:LandBuildings2022-09-012023-08-3108649020core:PlantMachinery2022-09-012023-08-3108649020core:Vehicles2022-09-012023-08-3108649020core:FurnitureFittings2022-09-012023-08-3108649020core:OfficeEquipment2022-09-012023-08-3108649020core:NetGoodwill2022-09-012023-08-3108649020core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3108649020core:ListedExchangeTraded2022-09-012023-08-3108649020core:UnlistedNon-exchangeTraded2022-09-012023-08-3108649020core:MoreThanFiveYears2022-09-012023-08-3108649020core:Non-currentFinancialInstruments2023-08-3108649020core:Non-currentFinancialInstruments2022-08-3108649020dpl:CostSales2022-09-012023-08-3108649020dpl:DistributionCosts2022-09-012023-08-3108649020core:LandBuildings2022-09-012023-08-3108649020core:PlantMachinery2022-09-012023-08-3108649020core:Vehicles2022-09-012023-08-3108649020core:FurnitureFittings2022-09-012023-08-3108649020core:OfficeEquipment2022-09-012023-08-3108649020dpl:AdministrativeExpenses2022-09-012023-08-3108649020core:NetGoodwill2022-09-012023-08-3108649020core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3108649020dpl:GroupUndertakings2022-09-012023-08-3108649020dpl:ParticipatingInterests2022-09-012023-08-3108649020dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3108649020core:ListedExchangeTraded2022-09-012023-08-3108649020dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3108649020core:UnlistedNon-exchangeTraded2022-09-012023-08-3108649020dpl:CostSales2021-09-012022-08-3108649020dpl:DistributionCosts2021-09-012022-08-3108649020core:LandBuildings2021-09-012022-08-3108649020core:PlantMachinery2021-09-012022-08-3108649020core:Vehicles2021-09-012022-08-3108649020core:FurnitureFittings2021-09-012022-08-3108649020core:OfficeEquipment2021-09-012022-08-3108649020dpl:AdministrativeExpenses2021-09-012022-08-3108649020core:NetGoodwill2021-09-012022-08-3108649020core:IntangibleAssetsOtherThanGoodwill2021-09-012022-08-3108649020dpl:GroupUndertakings2021-09-012022-08-3108649020dpl:ParticipatingInterests2021-09-012022-08-3108649020dpl:GroupUndertakingscore:ListedExchangeTraded2021-09-012022-08-3108649020core:ListedExchangeTraded2021-09-012022-08-3108649020dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-09-012022-08-3108649020core:UnlistedNon-exchangeTraded2021-09-012022-08-3108649020core:NetGoodwill2023-08-3108649020core:IntangibleAssetsOtherThanGoodwill2023-08-3108649020core:LandBuildings2023-08-3108649020core:PlantMachinery2023-08-3108649020core:Vehicles2023-08-3108649020core:FurnitureFittings2023-08-3108649020core:OfficeEquipment2023-08-3108649020core:AfterOneYear2023-08-3108649020core:WithinOneYear2023-08-3108649020core:ListedExchangeTraded2023-08-3108649020core:UnlistedNon-exchangeTraded2023-08-3108649020core:ShareCapital2023-08-3108649020core:SharePremium2023-08-3108649020core:RevaluationReserve2023-08-3108649020core:OtherReservesSubtotal2023-08-3108649020core:RetainedEarningsAccumulatedLosses2023-08-3108649020core:NetGoodwill2022-08-3108649020core:IntangibleAssetsOtherThanGoodwill2022-08-3108649020core:LandBuildings2022-08-3108649020core:PlantMachinery2022-08-3108649020core:Vehicles2022-08-3108649020core:FurnitureFittings2022-08-3108649020core:OfficeEquipment2022-08-3108649020core:AfterOneYear2022-08-3108649020core:WithinOneYear2022-08-3108649020core:ListedExchangeTraded2022-08-3108649020core:UnlistedNon-exchangeTraded2022-08-3108649020core:ShareCapital2022-08-3108649020core:SharePremium2022-08-3108649020core:RevaluationReserve2022-08-3108649020core:OtherReservesSubtotal2022-08-3108649020core:RetainedEarningsAccumulatedLosses2022-08-3108649020core:NetGoodwill2021-09-0108649020core:IntangibleAssetsOtherThanGoodwill2021-09-0108649020core:LandBuildings2021-09-0108649020core:PlantMachinery2021-09-0108649020core:Vehicles2021-09-0108649020core:FurnitureFittings2021-09-0108649020core:OfficeEquipment2021-09-0108649020core:AfterOneYear2021-09-0108649020core:WithinOneYear2021-09-0108649020core:ListedExchangeTraded2021-09-0108649020core:UnlistedNon-exchangeTraded2021-09-0108649020core:ShareCapital2021-09-0108649020core:SharePremium2021-09-0108649020core:RevaluationReserve2021-09-0108649020core:OtherReservesSubtotal2021-09-0108649020core:RetainedEarningsAccumulatedLosses2021-09-0108649020core:AfterOneYear2022-09-012023-08-3108649020core:WithinOneYear2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:CostValuation2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3108649020core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3108649020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3108649020core:Non-currentFinancialInstrumentscore:CostValuation2022-08-3108649020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-3108649020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-3108649020bus:Director12022-09-012023-08-3108649020bus:Director22022-09-012023-08-31

LARGE ATTALE MEDICAL LTD

Registered Number
08649020
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2023

LARGE ATTALE MEDICAL LTD
Company Information
for the year from 1 September 2022 to 31 August 2023

Directors

ATTALE, Shanika Rukmali Abeyratna, Dr
LARGE, Oliver Drury Helliwell, Dr

Registered Address

8 Grange Road
Hazlemere
High Wycombe
HP15 7QZ

Registered Number

08649020 (England and Wales)
LARGE ATTALE MEDICAL LTD
Balance Sheet as at
31 August 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets6494650
494650
Current assets
Debtors818,58016,352
Cash at bank and on hand48,80028,562
67,38044,914
Creditors amounts falling due within one year9(57,245)(14,009)
Net current assets (liabilities)10,13530,905
Total assets less current liabilities10,62931,555
Provisions for liabilities10(94)(123)
Net assets10,53531,432
Capital and reserves
Called up share capital100100
Profit and loss account10,43531,332
Shareholders' funds10,53531,432
The financial statements were approved and authorised for issue by the Board of Directors on 1 May 2024, and are signed on its behalf by:
LARGE, Oliver Drury Helliwell, Dr
Director
Registered Company No. 08649020
LARGE ATTALE MEDICAL LTD
Notes to the Financial Statements
for the year ended 31 August 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The principal activity of the company in the year under review was that of General medical practice.
4.Accounting policies
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Taxation policy
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
5.Employee information

20232022
Average number of employees during the year00
6.Property, plant and equipment

Plant & machinery

Office Equipment

Total

£££
Cost or valuation
At 01 September 221412,5332,674
At 31 August 231412,5332,674
Depreciation and impairment
At 01 September 22791,9452,024
Charge for year9147156
At 31 August 23882,0922,180
Net book value
At 31 August 2353441494
At 31 August 2262588650
7.Directors advances, credits and guarantees
The director's current account credit balance of £46,006 (2022: £5,358) relates to Dr Oliver Large Dr Shanika Attale.
8.Debtors within one year

2023

2022

££
Trade debtors / trade receivables1,1006,010
Other debtors17,48010,200
Prepayments and accrued income-142
Total18,58016,352
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
9.Creditors within one year

2023

2022

££
Taxation and social security9,4407,211
Other creditors46,0065,358
Accrued liabilities and deferred income1,7991,440
Total57,24514,009
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
10.Provisions for liabilities

2023

2022

££
Net deferred tax liability (asset)94123
Total94123